Showing 21-40 of 100 results
Elizabeth Stewart M.D.
Funded: 07-01-2016 through 06-30-2019
Funding Type: St. Baldrick's Scholar
Institution Location: Memphis, TN
Institution: St. Jude Children's Research Hospital

Pediatric cancer patients that have high-risk solid tumors can be very difficult to treat, particularly when their cancer has come back after previous treatment or has spread to multiple areas of the body. Dr. Stewart is looking for specific mutations in the tumors of these patients, and testing new cancer drugs to customize treatment to give patients with relapsed high-risk solid tumors with better treatment options. This grant is made with generous support from the Invictus Fund which was created in memory of Holden Gilkinson. It honors Holden'’s unconquerable spirit in his battle with bilateral Wilms tumor by funding cures and treatments to mitigate side and late effects of childhood cancer.

Birgit Knoechel M.D., Ph.D.
Funded: 07-01-2015 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Boston, MA
Institution: Dana-Farber Cancer Institute affiliated with Boston Children's Hospital, Harvard Medical School

T-cell acute lymphoblastic leukemia (T-ALL) is a cancer of childhood and young adults that originates from the white blood cells in the bone marrow. It is a disease for which the initial treatment is often unsuccessful and the disease comes back quickly. Dr. Knoechel is investigating the epigenetic state changes that are responsible for drug resistance in T-ALL to develop new treatment strategies for patients with relapsed leukemia.

Beata Chertok Ph.D.
Funded: 07-01-2015 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Ann Arbor, MI
Institution: University of Michigan affiliated with C.S. Mott Children’s Hospital

The immune system efficiently fights infections in the normal brain, but malfunctions in brain tumors. Dr. Chertok hopes to empower the immune system to fight tumors by delivering agents that alter immune system activities. To do this, Dr. Chertok's research aims to develop tiny devices the size of blood cells that carry agents in the blood stream and release them with pre-designed timing after localized activation from outside the body. These devices will be used to modify how the immune system responds to brain tumors. This approach could lead to safe and effective therapies for children with brain cancer. This grant is made with generous support from Griffin’s Guardians which was created by the Engles in memory of their son, Griffin. Their mission is to provide support and financial assistance to children battling cancer in Central New York, raise awareness about pediatric cancer and provide funding for research.

Lisa Roth M.D.
Funded: 07-01-2015 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: New York, NY
Institution: Weill Medical College of Cornell University affiliated with Weill Cornell Medical Center, New York-Presbyterian

Burkitt lymphoma is an aggressive cancer that occurs in children. Treatment requires intensive chemotherapy, which can have significant side effects. Targeted therapies, which kill cancer cells but spare healthy cells, are urgently needed. As the Jack’s Pack – We Still Have His Back St. Baldrick’s Scholar, Dr. Roth is investigating a promising new drug that kills Burkitt lymphoma by attacking a protein that the tumor needs to survive. This drug may treat Burkitt lymphoma with less side effects than chemotherapy. This grant is named in memory of Jack Klein who bravely battled Burkitts Lymphoma. Love for this special boy inspired family and friends to rally around him as “Jack’s Pack” with their cry, “We Got Jack’s Back”.

Agne Petrosiute M.D.
Funded: 07-01-2015 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Cleveland, OH
Institution: Case Western Reserve University

Despite successes in treating children with certain types of cancers, outcome remains poor for children with advanced solid tumors, including brain tumors and sarcomas. Dr. Petrosiute has investigated a protein called Cdk5 in medulloblastoma, finding that tumors become vulnerable to immune cell killing when Cdk5 function is disrupted, and this disruption, which can be achieved by drugs currently being tested in Phase I clinical trials, was correlated with a diminished production of immune-protective molecule called PD-L1 on tumor cells. This research aims to identify the molecular mechanisms of Cdk5 in order to enhance immunotherapy treatments. A portion of this grant was named for The Rebecca Allison Meyer Fund for Pediatric Cancer Research created to honor the memory of the joyful and spunky little girl who courageously battled brain cancer. Rebecca’s legacy lives on in the funding of promising glioblastoma research.

George-Lucian Moldovan Ph.D.
Funded: 07-01-2015 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Hershey, PA
Institution: Pennsylvania State University affiliated with Penn State Hershey Children's Hospital

Dr. Moldovan has identified a novel DNA damage repair mechanism that promotes the spread of leukemia cells. This research aims to investigate how leukemia cells fight DNA damage and potential therapies to target this mechanism.

Jennifer Kalish M.D., Ph.D.
Funded: 07-01-2015 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Philadelphia, PA
Institution: The Children's Hospital of Philadelphia affiliated with University of Pennsylvania

Beckwith-Wiedemann syndrome (BWS) is a genetic disorder that affects thousands of children. Up to 25% of children with BWS develop cancer, most commonly liver and kidney cancer. The same genetic changes that cause BWS also cause other types of cancer, however we do not currently understand how. Dr. Kalish's research is studying how genetic changes that cause BWS lead to cancer using a large group of BWS patients and models. The goal of this research is to use the knowledge gained from these models to improve care for patients with BWS and related cancers.

Tara Brinkman Ph.D.
Funded: 07-01-2015 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Memphis, TN
Institution: St. Jude Children's Research Hospital

Survivors of childhood brain tumors are at-risk for problems with developing social relationships. These problems can lead to feelings of isolation, loneliness and social anxiety. Dr. Brinkman believes this is due to changes in a survivor's brain due to their cancer and its treatment. Dr. Brinkman's research aims to examine how the structure and function of the brain is related to survivors’ understanding of social information and their social behavior. These results aim to help with the identification of treatments for social problems.

Gregory Aune M.D., Ph.D.
Funded: 09-01-2014 through 08-31-2018
Funding Type: St. Baldrick's Scholar
Institution Location: San Antonio, TX
Institution: University of Texas Health Science Center at San Antonio

Based on progress to date, Dr. Aune was awarded a new grant in 2017 to fund an additional year of this Scholar award. Survival from pediatric cancer approaches 80%, but long-term survivors have alarming rates of heart disease as adults. Dr. Aune's lab has developed models to study how pediatric cancer therapies affect the heart. This research aims to determine the potential for new chemotherapy agents to damage the heart. These strategies will lead to a better quality of life for children who survive cancer.

Samuel Cheshier M.D., Ph.D. 
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Palo Alto, CA
Institution: Stanford University affiliated with Lucile Packard Children’s Hospital

Based on progress to date, Dr. Cheshier was awarded a new grant in 2017 to fund an additional year of this Scholar award. Malignant primary brain tumors are the most common solid tumors in children and are a leading cause of death. Dr. Cheshier, Ty Louis Campbell Foundation St. Baldrick’s Scholar, aims to treat these cancers by stimulating the immune system to "eat" the cancer cells while leaving normal cells alone. This strategy combines a newly developed antibody protein that stimulates the "eating" cells of the immune system with known antibody proteins that can target brain tumors. Dr. Cheshier will then immediately translate these novel treatment combinations into clinical trials in children with malignant brain tumors. This grant is named for the Ty Louis Campbell Foundation, created in memory of Ty Louis Campbell, and funds innovative research and clinical trials specifically geared toward the treatment of the deadliest childhood cancers.

Yan Liu Ph.D.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Indianapolis, IN
Institution: Indiana University affiliated with IU Health Proton Therapy Center, Riley Hospital for Children

Based on progress to date, Dr. Liu was awarded a new grant in 2017 to fund an additional year of this Scholar award. Acute lymphoblastic leukemia (ALL) is the leading cause of cancer death in children. Despite improvements in treatment outcomes, a considerable number of patients relapse or do not respond to conventional chemotherapy. Dr. Liu's team recently found that an enzyme, called PRL2, is elevated in T-ALL cells, and that blocking PRL2 activity kills these cancer cells. This research aims to determine the effect of PRL2 inhibitors on T-ALL cells, in hopes it can be a new target in treatment of T-ALL.

Pratiti Bandopadhayay M.B.B.S., Ph.D.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Boston, MA
Institution: Dana-Farber Cancer Institute affiliated with Boston Children's Hospital, Harvard Medical School

Based on progress to date, Dr. Bandopadhayay was awarded a new grant in 2017 to fund an additional year of this Scholar award. Medulloblastoma is the most common malignant brain cancer of childhood. As the Hannah's Heroes St. Baldrick's Scholar, Dr. Bandopadhayay and her lab have shown that the drug JQ1 can hinder the cancer causing effects of a gene called MYC in one of the most aggressive types of medulloblastoma. This project aims to identify drugs which can be added to JQ1 to improve effectiveness. The results of this project will help determine combination therapies that can be used to treat children with this aggressive type of brain tumor. This grant is named for Hannah’s Heroes, a St. Baldrick’s Hero Fund created in honor of Hannah Meeson and pays tribute to her fight by raising awareness and funding for all childhood cancers because kids like Hannah “are worth fighting for.”

Hui Feng M.D., Ph.D.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Boston, MA
Institution: Boston University

Based on progress to date, Dr. Feng was awarded a new grant in 2017 to fund an additional year of this Scholar award. An amplified gene, MYCN, is found in ~30% of neuroblastomas, and is associated with highly aggressive tumors and extremely poor prognosis. Dr. Feng's work on T-cell leukemia recently showed that when a specific gene is turned off it will prevent tumor growth caused by a close relative of MYCN, C-MYC. This research aims to test if targeting this gene will suppress neuroblastoma development associated with MYCN activity.

Brenton Mar M.D., Ph.D.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Boston, MA
Institution: Boston Children's Hospital affiliated with Dana-Farber Cancer Institute, Harvard Medical School

Based on progress to date, Dr. Mar was awarded a new grant in 2017 to fund an additional year of this Scholar award. Although many children with acute lymphoblastic leukemia (ALL) are being cured today, a significant number still relapse. New targeted therapies that specifically attack the biology of ALL have great potential to improve outcomes; however, few specific biological vulnerabilities have been identified so far. Dr. Mar's team recently used a method to find novel biological vulnerabilities specific to ALL. As the Ben's Green Drakkoman Fund St. Baldrick's Scholar, Dr. Mar is studying those novel vulnerabilities in leukemia models, with the goal to understand why they are essential to ALL, and to determine their suitability for therapy. This grant is named for the Ben's Green Drakkoman Fund, created to honor the memory of Ben Stowell who battled osteosarcoma with an inspiring determination to live life fully. The fund is named after a super hero Ben created named the Green Drakkoman who defeats his enemy, the Evil Alien.

Jeffrey Magee M.D., Ph.D.
Funded: 07-01-2014 through 06-30-2017
Funding Type: St. Baldrick's Scholar
Institution Location: St. Louis, MO
Institution: Washington University in St. Louis affiliated with St. Louis Children's Hospital

Leukemia cells divide extensively, often by hijacking mechanisms that regulate normal stem cells. Dr. Magee is working to characterize genes that potentially regulate the growth of normal stem cells and leukemia cells. By characterizing these genes, Dr. Magee's team hopes that the proteins encoded by these genes will become targets for novel anti-leukemia therapies.

Lionel Blanc Ph.D.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Manhasset, NY
Institution: The Feinstein Institute for Medical Research affiliated with Steven and Alexandra Cohen Children's Medical Center

Based on progress to date, Dr. Blanc was awarded a new grant in 2017 to fund an additional year of this Scholar award. Diamond Blackfan Anemia is a rare genetic disease characterized by a dramatic decrease in red blood cells. Patients affected by this condition are more prone to develop cancers, like cancer of the bone. Dr. Blanc, Allied World St. Baldrick's Scholar, is studying the mechanism by which this cancer develops in these patients. This research aims to help understand how these tumors form, provide new targets for treatment, and improve cure rates. This grant is named for the Allied World team, whose employees have raised more than $1.1 million since 2008 for life-saving research through the St. Baldrick’s Foundation.

Jessica Shand M.D.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Rochester, NY
Institution: University of Rochester affiliated with Golisano Children's Hospital, Rochester, Strong Memorial Hospital

Based on progress to date, Dr. Shand was awarded a new grant in 2017 to fund an additional year of this Scholar award. Leukemia is a blood cancer that kills more children than any other cancer. Dr. Shand's work is based on the belief that leukemia behaves like some infections do, by tricking our body into thinking it's OK to set up shop there. Dr. Shand is studying how leukemia can send these “trick signals” to the part of our body that fights off infections, the immune system. This research aims to understand how these trick signals work, with the goal of turning them off so that the immune system can be used to cure leukemia.

Peter de Blank M.D., M.S.C.E.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Cincinnati, OH
Institution: Cincinnati Children's Hospital Medical Center affiliated with University of Cincinnati College of Medicine

Based on progress to date, Dr. de Blank was awarded a new grant in 2017 to fund an additional year of this Scholar award. Although therapies have improved for children with brain tumors, survival for malignant disease remains poor. Most of these children will have a recurrence of their tumor in the area of their original tumor, likely due to a tumor that was never fully removed. Dr. de Blank is investigating a new radiographic tool to diagnose brain tumors prior to surgery and define the extent of the tumor's invasion. This tool aims to improve outcomes by identifying children at risk for tumor recurrence and poor outcomes.

Eveline Barbieri M.D., Ph.D.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Houston, TX
Institution: Baylor College of Medicine affiliated with Texas Children's Hospital, Vannie E. Cook Jr. Children's Cancer and Hematology Clinic

Based on progress to date, Dr. Barbieri was awarded a new grant in 2017 to fund an additional year of this Scholar award. More than half of the patients with high-risk neuroblastoma will relapse despite intensive multimodal therapy. Treatments for these patients are challenging given disease heterogeneity, drug resistance, and toxicity. Dr. Barbieri’s project aims to develop novel targeted therapies for children with high-risk neuroblastoma whose disease is unresponsive to conventional therapies. By better understanding the metabolic changes occurring during the development of neuroblastoma, we will improve the clinical efficacy of current differentiating therapies for this aggressive disease.

Hui Li Ph.D.
Funded: 07-01-2014 through 06-30-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Charlottesville, VA
Institution: University of Virginia Children's Hospital

Based on progress to date, Dr. Li was awarded a new grant in 2017 to fund an additional year of this Scholar award. Alveolar rhabdomyosarcoma is one of the most common tumors in children and adolescents. No effective therapy is currently available for advanced staged patients, partly due to poor understanding of the disease. It is still considered mysterious because the exact cells from which the tumors develop (cells of origin) are not clear.  Like fingerprints, there are certain molecular events that are signatures of the tumor. By following these signatures Dr. Li, St. Baldrick’s V Scholar, and his team recently started to pick up hints that are potentially the cells of origin for this mysterious tumor. The goal of this study is a better understanding of the disease and to yield important information, which will guide the development of more effective therapeutic approaches. This grant is named for The V Foundation, a charitable organization dedicated to saving lives by helping to find a cure for cancer.